LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News NEWS FLASH L impact Sep 25, 2026, 10:34 AM UTC

Speedy Global Says Speedy Dongguan Enters Renovation Contract II With Shenzhen Jinjun

Speedy Global Holdings Ltd HKEX:540

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

540

Related stories

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement Eli Lilly and Company NYSE:LLY L impact | NEWS | Sep 25, 2026, 11:03 AM UTC Why the alternative to the 'clear and present' danger from bond yields is this AI-fueled market that's quietly outperformed By Barbara KollmeyerGoldman Sachs head of hedge fund coverage suggests investors look at Japanese stocks as a play on AI as U.S. equities face hurdles.The "clear and present danger L impact | NEWS | Sep 25, 2026, 11:02 AM UTC Buffalo Potash Corporation (BUFF) Completes Final Horizontal Well at Disley IPM Buffalo Potash Corporation completed the third and final horizontal well at its Disley Initial Production Module, installing all subsurface infrastructure for its HLD method and pr L impact | NEWS | Sep 25, 2026, 11:02 AM UTC Legend Biotech Reports 50% 5-Year PFS and 69% OS in CARVYKTI Cohort Legend Biotech reported CARTITUDE-2 Cohort A 5-year data: 50% of 20 RRMM patients remained progression- and treatment-free; 69.2% were alive at 5 years. Median PFS was 60.5 months; L impact | NEWS | Sep 25, 2026, 11:01 AM UTC C4 Therapeutics, Inc. (CCCC) Reports Early Biomarker and Safety Updates in Cemsidomide Combos C4 Therapeutics presented biomarker data showing T—cell activation with cemsidomide and said the 75 µg dose with elranatamab was declared safe, enabling expansion at 75 µg and esca L impact | NEWS | Sep 25, 2026, 11:01 AM UTC Fate Therapeutics, Inc. (FATE) Wins $15M CIRM Grant for FT819 Phase 2 RECLAIM-LN Fate Therapeutics received a $15.0M CIRM CLIN2 grant to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T in refractory SLE with lupus nep L impact | NEWS | Sep 25, 2026, 11:01 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.